Estrogen therapy for postmenopausal osteoporosis

Vitamin K2 Therapy for Postmenopausal Osteoporosis

Vitamin K may play an important role in the prevention of fractures in postmenopausal women with osteoporosis. Menatetrenone is the brand name of a synthetic vitamin K2 that is chemically identical to menaquinone-4. The present review study aimed to clarify the effect of menatetrenone on the skeleton in postmenopausal women with osteoporosis, by reviewing the results of randomized controlled tr...

Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis.

An ongoing need for safe and effective pharmacological therapies exists for postmenopausal osteoporosis, which imposes a significant burden on both women and the health-care system. Bazedoxifene is a novel selective estrogen receptor modulator with a unique tissue-selectivity profile. In phase 3 clinical trials of nearly 10,000 postmenopausal women, bazedoxifene was shown to significantly reduc...

intravenous bisphosphonates for postmenopausal osteoporosis

abstract numerous clinical studies have shown bisphoshonates (bps) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. the use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. to improve upon the subo...

The effect of sequential therapy for postmenopausal women with osteoporosis

BACKGROUND Osteoporosis, more likely to occur in postmenopausal women, is a chronic condition that usually requires a long-term treatment strategy, but the use of either antiresorptive or anabolic drugs should be limited to 18 to 24 months. Discontinuing antiosteoporosis drugs may result in rapidly declining bone mineral density (BMD). Therefore, many patients are treated with the sequential us...

Denosumab: an antifracture therapy for postmenopausal women with osteoporosis.